Welcome to our dedicated page for Gossamer Bio news (Ticker: GOSS), a resource for investors and traders seeking the latest updates and insights on Gossamer Bio stock.
Gossamer Bio, Inc. (NASDAQ: GOSS) is a late-stage, clinical biopharmaceutical company centered on the development and commercialization of seralutinib for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH‑ILD). The GOSS news feed on Stock Titan brings together company announcements, scientific updates, financial disclosures, and corporate developments that shape the investment and clinical narrative around its pulmonary hypertension programs.
News items for Gossamer Bio frequently cover progress in its registrational Phase 3 trials, including the PROSERA Study in PAH and the SERANATA Study in PH‑ILD. Investors and observers can follow updates on enrollment milestones, planned timelines for topline data, and key clinical endpoints such as six‑minute walk distance (6MWD), time to clinical worsening, and lung function measures. Scientific conference coverage, such as presentations at the European Respiratory Society (ERS) Congress, provides additional context on seralutinib’s mechanistic and translational data.
The GOSS news stream also reflects Gossamer Bio’s broader corporate and pipeline activities. This includes quarterly financial results and business updates, collaboration news with the Chiesi Group, stockholder meeting outcomes, and announcements related to its option agreement to acquire Respira Therapeutics and the investigational inhaled vardenafil candidate RT234. Regular disclosures of employment inducement stock option grants highlight hiring and equity compensation practices under Nasdaq Listing Rule 5635(c)(4).
By monitoring Gossamer Bio news on Stock Titan, readers can track how clinical data, regulatory milestones, scientific presentations, financial performance, and strategic transactions interact within the company’s focused pulmonary hypertension strategy. This page is intended as a central hub for GOSS-related headlines and press releases, helping users follow the evolution of its late-stage programs over time.
Gossamer Bio, Inc. (Nasdaq: GOSS) reported its Q2 2021 financial results, highlighting a net loss of $59.8 million, or $0.80 per share, an improvement from a net loss of $66.9 million, or $1.00 per share in Q2 2020. As of June 30, 2021, cash, cash equivalents, and marketable securities totaled $405.9 million, projected to fund operations through H2 2023. Key clinical updates include ongoing Phase 2 studies for seralutinib and GB004, with safety data showing promise in PAH treatment. However, Gossamer will discontinue further development of GB1275.
Gossamer Bio (Nasdaq: GOSS) announced it will report its Q2 2021 financial results on August 9, 2021. The live conference call will take place at 4:30 p.m. ET, where management will discuss the results and provide a corporate update. Investors can join the call via domestic at (833) 646-0603 or international at (929) 517-9782. A replay will be available for 30 days on their website, www.gossamerbio.com. Gossamer is focused on developing therapeutics in immunology, inflammation, and oncology.
Gossamer Bio (Nasdaq: GOSS) announced its participation in the 2021 Virtual Congress of the European Crohn’s and Colitis Organisation (ECCO), taking place from July 2-3 and 8-10. On July 8, William Sandborn, M.D., will present findings from the completed Phase 1b clinical trial for GB004, an oral gut-target HIF-1α stabilizer, focusing on target engagement and pharmacodynamic biomarkers in patients with mild-to-moderate ulcerative colitis. The presentation and poster will later be accessible on Gossamer Bio's website.
Gossamer Bio, Inc. (Nasdaq: GOSS) has announced the promotion of Richard Aranda, M.D., to Chief Medical Officer. Dr. Aranda, who has been with Gossamer since February 2018, previously served as Senior Vice President and Head of Clinical Development. His leadership is seen as crucial for the company's success in drug development, having extensive experience in clinical roles at Receptos and Novo-Nordisk. Gossamer Bio focuses on developing therapeutics in immunology, inflammation, and oncology, aiming to enhance patient care in these areas.
Gossamer Bio (Nasdaq: GOSS) has announced the appointment of Dr. Sandra Milligan to its Board of Directors. Dr. Milligan brings extensive experience from her role as Head of Research and Development at Organon, and previous positions at Merck and Genentech. CEO Faheem Hasnain praised her knowledge as invaluable for Gossamer’s mission to develop novel therapies in immunology, inflammation, and oncology. With a strong educational background in biology, psychology, medicine, and law, Dr. Milligan is expected to contribute significantly to the company's strategic direction.
Gossamer Bio, Inc. (Nasdaq: GOSS) reported its Q1 2021 financial results, noting a net loss of $57.6 million or $0.78 per share, compared to a net loss of $54.1 million or $0.87 per share in Q1 2020. Cash and equivalents stood at $453.3 million, sufficient to fund operations into 2023. Key clinical updates include ongoing trials for seralutinib in pulmonary arterial hypertension, GB004 for inflammatory bowel disease, and GB1275 for solid tumors, with results expected in 2022. The company also announced leadership promotions.
Gossamer Bio, Inc. (GOSS) announced that Chief Scientific Officer Luisa Salter-Cid will resign effective April 30, 2021. Laura Carter, previously Senior Vice President of Research & Translational Biology, will succeed her. Chairman and CEO Faheem Hasnain acknowledged Salter-Cid's contributions in developing the pre-clinical pipeline and welcomed Carter, highlighting her extensive experience in immunology and clinical development. Carter's background includes leadership roles in various biopharmaceutical firms, enhancing her capability to drive Gossamer’s clinical programs forward.
Gossamer Bio (Nasdaq: GOSS) has promoted Caryn Peterson to Executive Vice President, Regulatory Affairs, effective immediately. In her new role, Peterson will lead the company's regulatory and quality functions and develop global regulatory strategies for clinical and pre-clinical programs. She has been with Gossamer since 2018, previously serving as Senior Vice President, Regulatory & Quality. CEO Faheem Hasnain highlighted her strategic acumen and strong relationships with regulatory agencies as vital for advancing Gossamer's clinical portfolio, which includes candidates like seralutinib and GB004.
Gossamer Bio, Inc. (Nasdaq: GOSS) reported its financial results for Q4 and the full year 2020, reflecting a net loss of $64.6 million for the quarter and $243.4 million for the year. R&D expenses for Q4 were $38.9 million, down from $42.6 million in 2019, while full-year R&D expenses increased to $160.9 million. The company has $512.6 million in cash and equivalents, expected to fund operations into 2023. Notable clinical trials include seralutinib for PAH and GB004 for IBD, with data expected in 2022.
Gossamer Bio, a clinical-stage biopharmaceutical company (Nasdaq: GOSS), announced it will report its fourth quarter and full-year 2020 financial results on February 25, 2021. A conference call and webcast will follow at 8:30 a.m. ET that same day, providing an update on the financial results and corporate developments. Investors can access the live webcast via the company's website. Gossamer Bio is dedicated to developing therapeutics in immunology, inflammation, and oncology, aiming to become a leader in these fields.